146 related articles for article (PubMed ID: 19475723)
21. Levetiracetam, a new antiepileptic agent: lack of in vitro and in vivo pharmacokinetic interaction with valproic acid.
Coupez R; Nicolas JM; Browne TR
Epilepsia; 2003 Feb; 44(2):171-8. PubMed ID: 12558570
[TBL] [Abstract][Full Text] [Related]
22. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group.
Shorvon SD; Löwenthal A; Janz D; Bielen E; Loiseau P
Epilepsia; 2000 Sep; 41(9):1179-86. PubMed ID: 10999557
[TBL] [Abstract][Full Text] [Related]
23. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study.
Ramael S; Daoust A; Otoul C; Toublanc N; Troenaru M; Lu ZS; Stockis A
Epilepsia; 2006 Jul; 47(7):1128-35. PubMed ID: 16886975
[TBL] [Abstract][Full Text] [Related]
24. A prospective pilot study of levetiracetam for body dysmorphic disorder.
Phillips KA; Menard W
CNS Spectr; 2009 May; 14(5):252-60. PubMed ID: 19407724
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy.
Ben-Menachem E; Gilland E
Seizure; 2003 Apr; 12(3):131-5. PubMed ID: 12651076
[TBL] [Abstract][Full Text] [Related]
26. Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus.
Möddel G; Bunten S; Dobis C; Kovac S; Dogan M; Fischera M; Dziewas R; Schäbitz WR; Evers S; Happe S
J Neurol Neurosurg Psychiatry; 2009 Jun; 80(6):689-92. PubMed ID: 19448097
[TBL] [Abstract][Full Text] [Related]
27. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy.
Ben-Menachem E; Edrich P; Van Vleymen B; Sander JW; Schmidt B
Epilepsy Res; 2003 Feb; 53(1-2):57-64. PubMed ID: 12576168
[TBL] [Abstract][Full Text] [Related]
28. Tolerability, safety, and side effects of levetiracetam versus phenytoin in intravenous and total prophylactic regimen among craniotomy patients: a prospective randomized study.
Fuller KL; Wang YY; Cook MJ; Murphy MA; D'Souza WJ
Epilepsia; 2013 Jan; 54(1):45-57. PubMed ID: 22738092
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of high oral doses of levetiracetam in children with epilepsy.
Obeid M; Pong AW
Epilepsy Res; 2010 Sep; 91(1):101-5. PubMed ID: 20663645
[TBL] [Abstract][Full Text] [Related]
30. Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial.
Coppola G; Franzoni E; Verrotti A; Garone C; Sarajlija J; Operto FF; Pascotto A
Brain Dev; 2007 Jun; 29(5):281-4. PubMed ID: 17055681
[TBL] [Abstract][Full Text] [Related]
31. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF
Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011
[TBL] [Abstract][Full Text] [Related]
32. Impact of generic substitution on levetiracetam serum concentration-A prospective study in an outpatient setting.
Reimers A; Olsson P; Nilsson J; Hoff E; Reis M; Strandberg M; Lundgren A; Källén K
Epilepsy Res; 2017 Aug; 134():54-61. PubMed ID: 28595756
[TBL] [Abstract][Full Text] [Related]
33. Levetiracetam: safety and efficacy in neonatal seizures.
Ramantani G; Ikonomidou C; Walter B; Rating D; Dinger J
Eur J Paediatr Neurol; 2011 Jan; 15(1):1-7. PubMed ID: 21094062
[TBL] [Abstract][Full Text] [Related]
34. Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor.
Handforth A; Martin FC
Mov Disord; 2004 Oct; 19(10):1215-21. PubMed ID: 15390011
[TBL] [Abstract][Full Text] [Related]
35. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures.
Glauser TA; Ayala R; Elterman RD; Mitchell WG; Van Orman CB; Gauer LJ; Lu Z;
Neurology; 2006 Jun; 66(11):1654-60. PubMed ID: 16641323
[TBL] [Abstract][Full Text] [Related]
36. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.
Steinhoff BJ; Somerville ER; Van Paesschen W; Ryvlin P; Schelstraete I
Epilepsy Res; 2007 Aug; 76(1):6-14. PubMed ID: 17681453
[TBL] [Abstract][Full Text] [Related]
37. Intravenous levetiracetam treatment in status epilepticus: A prospective study.
Atmaca MM; Orhan EK; Bebek N; Gurses C
Epilepsy Res; 2015 Aug; 114():13-22. PubMed ID: 26088881
[TBL] [Abstract][Full Text] [Related]
38. Levetiracetam extended release for the treatment of patients with partial-onset seizures: A long-term, open-label follow-up study.
Chung S; Ceja H; Gawłowicz J; McShea C; Schiemann J; Lu S
Epilepsy Res; 2016 Feb; 120():7-12. PubMed ID: 26716580
[TBL] [Abstract][Full Text] [Related]
39. Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial.
Bähr O; Hermisson M; Rona S; Rieger J; Nussbaum S; Körtvelyessy P; Franz K; Tatagiba M; Seifert V; Weller M; Steinbach JP
Acta Neurochir (Wien); 2012 Feb; 154(2):229-35; discussion 235. PubMed ID: 21909835
[TBL] [Abstract][Full Text] [Related]
40. Adjunctive levetiracetam in patients aged 1 month to <4 years with partial-onset seizures: subpopulation analysis of a prospective, open-label extension study of up to 48 weeks.
Piña-Garza JE; Schiemann-Delgado J; Yang H; Duncan B; Hadac J; Hunter SJ
Clin Ther; 2010 Oct; 32(11):1935-50. PubMed ID: 21095488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
